Table S2 from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
crossref(2023)
摘要
PK parameters for M5 following a single dose (Day 1) and multiple doses (Day 15)
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要